Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PCNA | P12004 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.30 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.30 |
| ▸ | PRKACA | P17612 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8359643 | 0.92 | LMNA (0.47) | LMNAMAP2K1MAPK1TSHRPCNA | |
| SCHEMBL8978118 | 0.90 | LMNA (0.44) | LMNAMAP2K1MAPK1TSHRPCNA | |
| SCHEMBL622562 | 0.87 | LMNA (0.48) | LMNAMAP2K1CYP2C19HIF1AROCK2 | |
| SCHEMBL8978065 | 0.80 | LMNA (0.74) | LMNAMAPK1TSHRPCNA | |
| SCHEMBL11299901 | 0.79 | LMNA (0.58) | LMNAMAP2K1POLBTDP1PIN1 | |
| SCHEMBL3430438 | 0.79 | LMNA (0.58) | LMNAMAP2K1CYP2C19HIF1A | |
| SCHEMBL9284458 | 0.78 | LMNA (0.38) | LMNAMAPK1TSHRCYP2C19HIF1A | |
| SCHEMBL8764309 | 0.78 | TPMT (0.45) | LMNAMAP2K1MAPK1PCNAPOLB | |
| SCHEMBL2763618 | 0.78 | LMNA (0.56) | LMNAMAP2K1POLBTDP1CYP2C19 | |
| SCHEMBL25981186 | 0.78 | LMNA (0.60) | LMNAMAP2K1POLBTDP1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025073833-A1 | OPTIMIZED PROCESS FOR THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING SPA (IT) | 2025-04-10 | — | — | WO | claimed |
| EP-0470247-B1 | REVERSED PHASE CHROMATOGRAPHIC PROCESS | MALLINCKRODT INC (US) | 1997-04-16 | — | — | EP | claimed |
| WO-2025073833-A1 | OPTIMIZED PROCESS FOR THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING SPA (IT) | 2025-04-10 | — | — | WO | disclosed |
| EP-2975021-B1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING SPA (IT) | 2017-07-26 | — | — | EP | disclosed |
| EP-1353899-B1 | A PROCESS FOR THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING SPA (IT) | 2016-01-20 | — | — | EP | disclosed |
| EP-2975021-A1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | Bracco Imaging SPA (IT) | 2016-01-20 | — | — | EP | disclosed |
| US-7368101-B2 | Process for the preparation of iopamidol and the new intermediates therein | BRACCO IMAGING S.P.A. (IT) | 2008-05-06 | — | — | US | disclosed |
| US-20060106253-A1 | Process for the preparation of iopamidol and the new intermediates therein | BRACCO IMAGING S.P.A. (IT) | 2006-05-18 | — | — | US | disclosed |
| US-7034183-B2 | Process for the preparation of iopamidol and the new intermediated therein | BRACCO IMAGING S.P.A. (IT) | 2006-04-25 | — | — | US | disclosed |
| US-20040082812-A1 | Process for the preparation of iopamidol and the new intermediated therein | BRACCO IMAGING S.P.A. (IT) | 2004-04-29 | — | — | US | disclosed |
| EP-1353899-A1 | A PROCESS FOR THE PREPARATION OF IOPAMIDOL AND THE NEW INTERMEDIATES THEREIN | Bracco Imaging S.p.A. (IT) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002044132-A1 | A PROCESS FOR THE PREPARATION OF IOPAMIDOL AND THE NEW INTERMEDIATES THEREIN | BRACCO IMAGING S.P.A. (IT) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106253-A1 | Process for the preparation of iopamidol and the new intermediates therein | C9, CBR3, INSR | LMNA 1160/4885MAP2K1 3453/4885MAPK1 703/4885 |
| US-20040082812-A1 | Process for the preparation of iopamidol and the new intermediated therein | INSR, ACVRL1, CBR3 | LMNA 1132/4885MAP2K1 4197/4885MAPK1 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.